Takeda Pharmaceuticals America, Inc.
Cambridge, MA Part of Takeda Pharmaceutical Company LIMITED
- UEI
- ENNFDLWFC6L1
- CAGE
- 3FLV7
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Takeda Pharmaceutical Company LIMITED
Parent
WZM4GN1RQAK9
- Takeda Pharmaceuticals America, Inc. ENNFDLWFC6L1
-
Takeda Pharmaceutical Company LIMITED
Parent
WZM4GN1RQAK9
- SAM.gov registration date
- Physical address
- 40 Landsdowne St, Cambridge, MA 02139, USA
- Website
- takedaoncology.com
- Founded
- 1993
- Employees
- 1K-5K
- Estimated annual revenue
- $250M-$500M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Takhzyro 150 MG | Veterans Integrated Service Network 5 | $0 | |
| Takhzyro 150 MG | Veterans Integrated Service Network 5 | $38,098 | |
| Takhzyro 150 MG | Veterans Integrated Service Network 5 | $38,098 | |
| Gattex 5 MG | Veterans Integrated Service Network 5 | $34,605 | |
| Takhzyro 150 MG | Veterans Integrated Service Network 5 | $38,098 |
About Takeda Pharmaceuticals America, Inc.
Takeda Pharmaceuticals America, Inc., a foreign-owned subsidiary of Japan-based Takeda Pharmaceutical Company Limited, supplies specialty oncology pharmaceuticals to the federal government as a prime contractor through full-and-open competitive procurement. The company is a large, for-profit manufacturer headquartered in Cambridge, Massachusetts, with no small business set-aside designations across its federal footprint. Takeda operates exclusively in pharmaceutical manufacturing (NAICS 325412, PSC Drugs and Biologicals) and competes without claiming minority, women-owned, or veteran status.
Takeda's federal business centers on ICLUSIG (ponatinib), a targeted cancer therapy for chronic myeloid leukemia and acute lymphoblastic leukemia. The company supplies the drug in multiple dosage strengths (10 milligram through 45 milligram tablets) through the General Services Administration's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Recent representative work includes a $173.7 million delivery order from Veterans Integrated Service Network 20 for ICLUSIG 30mg tablets through May 2025; multiple $42 thousand to $57 thousand delivery orders from VISN 5, VISN 20, and VISN 21 for ICLUSIG in various strengths; and $14 thousand orders from the Federal Correctional Complex Florence for foundation care pharmaceutical chemotherapy. The vast majority of task orders run $13 thousand to $43 thousand per order, reflecting pharmaceutical commodity supply patterns.
Customer concentration sits overwhelmingly with the Department of Veterans Affairs, which accounts for the totality of federal spending. Within the VA system, the top three purchasing entities by award count are VISN 20 (40 awards, $2.7 million combined potential value), VISN 5 (35 awards, $557 thousand), and VISN 9 (27 awards, $345 thousand), covering 84% of awards. By potential value, however, VISN 12 dominates with 15 awards carrying $3.31 billion in combined potential value—a stark concentration signal driven by the parent indefinite delivery vehicle ceiling. The Federal Correctional Complex Florence accounts for seven awards valued at $129 thousand total.
Takeda holds three major parent vehicles, all GSA Schedule 61-IB derivatives. The anchor is a $2.89 billion Federal Supply Schedule contract (multiple award, September 2025 through September 2030, administered by VISN 12) generating 145 of 147 awards with $185.4 million combined potential value. Two single-award Blanket Purchase Agreements with the VA National Acquisition Center specifically for ICLUSIG carry $43.8 million (October 2025 through October 2026) and $123.5 million (October 2024 through September 2025) potential values. A third BPA worth $851.9 million (March 2026 through March 2027 with four one-year option periods) was awarded in March 2026. These indefinite delivery vehicles enable VA medical facilities across multiple VISNs to place delivery orders without separate competitive procurements.
Activity has grown substantially: thirteen awards in 2022 to thirty-one in 2024, with twenty in 2025 and six in 2026 (through May). Recompete exposure in the next twenty-four months is minimal—only one award worth $57 thousand reaches ultimate completion inside that window, though the major parent vehicles themselves are subject to renewal or recompete cycles in 2025 and 2026. Takeda operates exclusively as a prime contractor; the source contains zero sub-award records, indicating the company does not subcontract to other federal suppliers. Performance occurs at Earth City, Missouri and Cambridge, Massachusetts, with orders placed by nine distinct VA VISNs plus the Federal Correctional Complex Florence. The company's federal contracting presence is laser-focused: oncology pharmaceutical supply to the VA healthcare system, with no diversification into other agencies, product lines, or service categories evident in the award record.
Contract vehicles
Quick answers
What is Takeda Pharmaceuticals America, Inc.'s UEI?
Takeda Pharmaceuticals America, Inc.'s Unique Entity ID (UEI) in SAM.gov is ENNFDLWFC6L1.
What is Takeda Pharmaceuticals America, Inc.'s CAGE code?
Takeda Pharmaceuticals America, Inc.'s CAGE code is 3FLV7.
What is Takeda Pharmaceuticals America, Inc.'s primary NAICS code?
Takeda Pharmaceuticals America, Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Takeda Pharmaceuticals America, Inc. located?
Takeda Pharmaceuticals America, Inc.'s physical address in SAM.gov is 40 Landsdowne St, Cambridge, MA 02139, USA.
Is Takeda Pharmaceuticals America, Inc. registered in SAM.gov?
Yes. Takeda Pharmaceuticals America, Inc.'s SAM.gov registration is active through October 1, 2027.
Who is Takeda Pharmaceuticals America, Inc.'s parent company?
Takeda Pharmaceuticals America, Inc. is part of Takeda Pharmaceutical Company LIMITED.
Which contract vehicles does Takeda Pharmaceuticals America, Inc. hold?
Takeda Pharmaceuticals America, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Takeda Pharmaceuticals America, Inc.'s most recent federal award?
Takeda Pharmaceuticals America, Inc.'s most recent federal contract award is Takhzyro 150 MG (36C24526N0839), from Veterans Integrated Service Network 5, on August 27, 2026.
On GovTribe
See Takeda Pharmaceuticals America, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors